The voltage-gated cardiac Na + channel (Na v 1.5), encoded by the SCN5A gene, conducts the inward depolarizing cardiac Na + current (I Na ) and is vital for normal cardiac electrical activity. Inherited loss-of-function mutations in SCN5A lead to defects in the generation and conduction of the cardiac electrical impulse and are associated with various arrhythmia phenotypes 1 . Here we show that sirtuin 1 deacetylase (Sirt1) deacetylates Na v 1.5 at lysine 1479 (K1479) and stimulates I Na via lysine-deacetylation-mediated trafficking of Na v 1.5 to the plasma membrane. Cardiac Sirt1 deficiency in mice induces hyperacetylation of K1479 in Na v 1.5, decreases expression of Na v 1.5 on the cardiomyocyte membrane, reduces I Na and leads to cardiac conduction abnormalities and premature death owing to arrhythmia. The arrhythmic phenotype of cardiac-Sirt1-deficient mice recapitulated human cardiac arrhythmias resulting from loss of function of Na v 1.5. Increased Sirt1 activity or expression results in decreased lysine acetylation of Na v 1.5, which promotes the trafficking of Na v 1.5 to the plasma membrane and stimulation of I Na . As compared to wild-type Na v 1.5, Na v 1.5 with K1479 mutated to a nonacetylatable residue increases peak I Na and is not regulated by Sirt1, whereas Na v 1.5 with K1479 mutated to mimic acetylation decreases I Na . Na v 1.5 is hyperacetylated on K1479 in the hearts of patients with cardiomyopathy and clinical conduction disease. Thus, Sirt1, by deacetylating Na v 1.5, plays an essential part in the regulation of I Na and cardiac electrical activity. Na v 1.5, encoded by the SCN5A gene, has a critical role in the cardiac action potential 2 . Inherited mutations in SCN5A lead to cardiacarrhythmia syndromes (Brugada syndrome, long-QT syndrome type 3 and inherited conduction disease) 1 , and pharmacologic agents that decrease cardiac sodium current can be proarrhythmic 3 . Post-translational modifications of Na v 1.5 (phosphorylation, methylation, alanine-N-terminal acetylation, ubiquitination and palmitoylation) modulate its biophysical properties and its membrane localization 4, 5 . Additionally, Na v 1.5 is regulated by the cellular energetic state; NAD + /NADH alters membrane localization of the channel, at least in part, through protein kinase C (PKC)-mediated phosphorylation 6, 7 . However, the role of dynamic lysine acetylation in governing Na v 1.5 function is not known. Recognizing that Na v 1.5 membrane localization is influenced by NAD + (ref. 6) , and that Sirt1 is an NAD + -dependent lysine deacetylase, we asked whether Sirt1 regulates the inward depolarizing sodium current (I Na ) and cardiac electrical activity by deacetylating Na v 1.5.
We first tested whether Na v 1.5 physically interacts with Sirt1. Native Na v 1.5 from neonatal rat cardiomyocytes and adult mouse hearts coprecipitated with Sirt1 (Fig. 1a) , and Sirt1 colocalized with Na v 1.5 on the cell surface of mouse cardiomyocytes (Fig. 1b) . We next examined the effect of Sirt1 on I Na conducted by Na v 1.5 in a heterologous expression system. In human embryonic kidney (HEK) 293 cells expressing Na v 1.5, overexpression of Sirt1 increased I Na , as assessed by whole-cell patch clamping, whereas the inhibition of Sirt1 by overexpression of catalytically inactive dominant-negative Sirt1 (H363Y) decreased I Na (Fig. 1c) . Similarly, overexpression of Sirt1 in neonatal rat cardiomyocytes increased endogenous I Na (Fig. 1d) without changing Na v 1.5 expression (Supplementary Fig. 1a,b) , whereas treatment with Ex-243, a pharmacologic Sirt1 inhibitor, decreased I Na (Fig. 1d) . Sirt1 overexpression in HEK293 cells resulted in a small (≈2-mV) hyperpolarizing shift in the voltage for half-maximal activation (V 1/2 ) of I Na from −39.8 mV to −41.9 mV (Supplementary Table 1 ). However, no substantial differences were observed in other kinetic parameters of Na v 1.5, including steady-state inactivation, development of intermediate inactivation or recovery from inactivation ( Supplementary Fig. 2 Sirtuin 1 regulates cardiac electrical activity by deacetylating the cardiac sodium channel and Supplementary Table 1) . To determine whether Na v 1.5 is governed by endogenous Sirt1, we generated mice with cardiomyocytespecific deletion of Sirt1 (cSirt1 −/− ; Supplementary Fig. 1c,d ) and measured I Na in ventricular myocytes isolated from 6-7-month-old mice. I Na was significantly lower in cSirt1 −/− myocytes than in control littermate Sirt1 fl/fl myocytes ( Fig. 1e-g ), despite an increase in total Na v 1.5 protein in cSirt1 −/− hearts (Supplementary Fig. 1e ). There were no changes in the current-voltage relationship (Supplementary  Table 2 ), steady-state inactivation, recovery from slow and fast inactivation, late sodium current ( Supplementary Fig. 3a,b) or the time constants of the decay phase of I Na (Supplementary Table 2 ) between cSirt1 −/− and Sirt1 fl/fl cardiomyocytes.
Next, we tested whether Na v 1.5 is lysine acetylated and whether Sirt1 regulates this acetylation. Inhibition of Sirt1 with nicotinamide (NAM) stimulated the acetylation of full-length Na v 1.5 expressed in HEK293 cells, whereas overexpression of Sirt1 or stimulation of Sirt1 activity with resveratrol decreased the levels of lysine acetylation of Na v 1.5 (Fig. 2a) . In addition, inhibition of Sirt1 in neonatal rat cardiomyocytes, either by adenoviral overexpression of dominant-negative Sirt1 (H363Y) or pharmacologically by a Sirt1 inhibitor (Ex-243), led to hyperacetylation of native Na v 1.5 ( Supplementary Fig. 4a and Fig. 1d) . To identify the acetylated lysine residue(s) in Na v 1.5 that are deacetylated by Sirt1, we focused on the lysine-rich intracellular region of Na v 1.5-linking domains III and IV (III-IV interdomain linker), which is 61 amino acids in length. This interdomain linker is highly conserved among voltage-gated sodium channels and has an important role in the regulation of channel localization and kinetics 4 . Moreover, inherited mutations and deletions of lysine residues in this region are associated with clinical arrhythmia phenotypes 8, 9 . We generated a recombinant fusion protein in which glutathione S-transferase (GST) is fused to the III-IV interdomain linker (GST-Na v 1.5 (III-IV)), and found that this fusion protein interacted with Sirt1 using in vitro co-precipitation (Fig. 2b) . Acetylation of GST-Na v 1.5 (III-IV) by p300/CREB-binding protein (CBP) acetylase increased this interaction (Fig. 2b) . Moreover, similarly to its effects on fulllength Na v 1.5, manipulation of Sirt1 expression or activity altered the acetylation of GST-Na v 1.5 (III-IV) expressed in HEK293 cells (Supplementary Fig. 4b ). To identify the acetylated lysine(s) in the region of Na v 1.5 that is deacetylated by Sirt1, we performed mass spectrometry (MS). We acetylated recombinant GST-Na v 1.5 (III-IV) with p300/CBP and then treated the acetylated protein with Sirt1 in vitro (Supplementary Fig. 5a ). After acetylation with p300/CBP, we identified the acetylated peptide k Ac LGGQDIFmTEEQK by MS/MS analysis ( Supplementary Fig. 5b,c) . The acetylated lysine in this peptide corresponds to the highly conserved lysine 1479 (K1479) in full-length Na v 1.5. Liquid chromatography (LC)-MS/MS analysis failed to detect this acetylated peptide in untreated GST-Na v 1.5 (III-IV) peptide, and the abundance of this acetylated peptide was markedly decreased when p300-acetylated GST-Na v 1.5 (III-IV) was treated with Sirt1 ( Supplementary Fig. 5c ). To verify K1479 as a target of Sirt1, we mutated this residue in GST-Na v 1.5 (III-IV) to a nonacetylatable arginine (K1479R) and assessed its acetylation when expressed in HEK293 cells. As compared to the WT GST-Na v 1.5 (III-IV) peptide, acetylation of the K1479R mutant GST-Na v 1.5 (III-IV) peptide was decreased; moreover, knockdown of Sirt1 increased acetylation of wild-type GST-Na v 1.5 (III-IV) but not that of the K1479R mutant (Fig. 2c) . To further assess Na v 1.5 acetylation, we generated an antibody highly specific against the acetylated K1479 immunogen ( Supplementary Fig. 5d-f) . Using this antibody, we found that Sirt1 overexpression in HEK293 cells led to deacetylation of K1479 in GST-Na v 1.5 (III-IV) (Fig. 2d) . Similarly, K1479 in full-length Na v 1.5 expressed in HEK293 cells was deacetylated when Sirt1 was overexpressed but hyperacetylated when Sirt1 activity was inhibited by either treatment with NAM or the expression of dominant-negative Sirt1 (H363Y) (Fig. 2e,f and Supplementary  Fig. 4b ). Moreover, K1479 was hyperacetylated in isolated cardiomyocytes and whole hearts of cSirt1 −/− mice, as compared to those of littermate mice in which exon 4 of Sirt1 is flanked by LoxP (Sirt1 fl/fl ) ( Fig. 2g-i) . We also tested the role of other HDACs in the regulation of K1479 acetylation. Trichostatin A (TSA), an inhibitor of class I and II HDACs, does not inhibit class III HDACs such as Sirt1. Treatment of HEK293 cells expressing Na v 1.5 with TSA also resulted in increased levels of acetylated K1479 ( Supplementary Fig. 4c ), which indicates that acetylated K1479 is also targeted by nonsirtuin deacetylases. Next, we explored the importance of K1479 to a Sirt1-induced increase in I Na . We generated full-length Na v 1.5-mutant constructs and expressed them in HEK293 cells: a K1479Q construct was designed to mimic a constitutively acetylated channel and K1479R and K1479A constructs were designed to be nonacetylatable. The expression of acetylation-mimic Na v 1.5 decreased peak I Na as compared to wild-type Na v 1.5, whereas the expression of nonacetylatable Na v 1.5 increased I Na (Fig. 3a,b) . Moreover, in contrast to I Na conducted by wild-type Na v 1.5, Sirt1 did not stimulate I Na in HEK293 cells expressing nonacetylatable Na v 1.5 (compare Fig. 3c and Fig. 1c) , and the expression of dominant-negative Sirt1 (H363Y) failed to inhibit I Na conducted through nonacetylatable Na v 1.5 (compare Fig. 3d and Fig. 1c) . The kinetic properties of I Na conducted by nonacetylatable Na v 1.5 (K1479A and K1479R) were similar to those of wild-type Na v 1.5; they showed no significant differences in steady-state activation, inactivation, development of intermediate inactivation or recovery from inactivation (Supplementary Tables 1  and 3 and Supplementary Fig. 2c,d) . As compared to wild-type Na v 1.5, the K1479Q acetylation mimic shifted the steady-state inactivation curve to more positive potentials (Supplementary Table 3 and Supplementary Fig. 2d ), indicating that an increased fraction of channels is available for activation at normal resting membrane potential. However, despite this depolarizing shift in steady-state inactivation, I Na conducted by K1479Q Na v 1.5 was lower than that conducted by wild-type Na v 1.5, which indicates that decreased current density is due to the reduced membrane localization of K1479Q Na v 1.5.
Given the observations that Na v 1.5 and Sirt1 colocalize at the cardiomyocyte membrane (Fig. 1b) ; that there is an appreciable decrease in the membrane localization of Na v 1.5 in cSirt1 −/− cardiomyocytes (Fig. 2g) ; and that Sirt1 affects the amplitude of I Na but not its kinetics, we explored the role of Sirt1 in the trafficking of Na v 1.5 to the plasma membrane. Activation of protein kinase A increases Na v 1.5 trafficking to the plasma membrane 10 , whereas PKC activation results in decreased abundance of channels resident in the membrane 11 . Notably, a conserved serine residue (S1503), which resides in the III-IV interdomain linker, serves as a phospho-acceptor site that mediates the PKC-induced decrease in the cell surface expression of the channel 7 . To test the possibility that K1479 acetylation, similarly to S1503 phosphorylation, decreases cell surface expression of Na v 1.5, we performed quantitative immunofluorescence of cardiomyocytes isolated from cSirt1 −/− mice using an antibody that detects only an extracellular epitope of Na v 1.5. cSirt1 −/− cardiomyocytes showed a significant decrease in their expression of Na v 1.5 at the cell membrane as compared to cSirt1 fl/fl controls (Fig. 3e,f, Supplementary  Fig. 1f and Supplementary Videos 1 and 2) . Moreover, a quantitative cell surface luminescence assay using this antibody in HEK293 cells expressing Na v 1.5 showed that expression of wild-type Sirt1 increased cell surface expression of the channel, whereas expression of dominant-negative Sirt1 (H363Y) decreased the abundance of Na v 1.5 at the cell membrane (Fig. 3g-i) . Notably, Sirt1 expression did not increase cell surface expression of nonacetylatable (K1479A) Na v 1.5 (Fig. 3i) , which underscores the requirement for K1479 acetylation in the regulation of Na v 1.5 trafficking by Sirt1. Next, we examined whether cSirt1 −/− mice showed cardiac conduction abnormalities that are similar to those in Scn5a-heterozygousknockout mice and those observed in patients with loss-of-function SCN5A mutations 12 . Surface electrocardiograms (EKGs) performed on 4-5-month-old cSirt1 −/− and Sirt1 fl/fl mice showed no differences in baseline EKG intervals (Supplementary Table 4) , which suggests that a lack of Sirt1 in cardiomyocytes has no adverse impact on cardiac electrical activity and conduction at this age. However, chronologic aging unmasked notable differences in cardiac conduction parameters between cSirt1 −/− and Sirt1 fl/fl mice. At approximately 9 months of age, cSirt1 −/− mice exhibited prolongation of the QRS and QTc intervals as compared to aged-matched Sirt1 fl/fl mice (P < 0.05 for each; Supplementary Table 4), indicating that the absence of Sirt1 in cardiomyocytes leads to age-dependent impairment of conductance of the electrical impulse and delayed ventricular repolarization, similar to prior reports on Scn5a +/− mice 12 . Expression of the gapjunction protein connexin 43 was not diminished in the hearts of cSirt1 −/− mice (Supplementary Fig. 6a) , which indicates that a defect in cell-to-cell electrical-impulse conduction likely does not contribute to the cardiac conduction abnormalities. To complement these studies, we intraperitoneally (i.p.) administered the Sirt1 inhibitor Ex-527 to ~10-11-month-old wild-type (Scn5a +/+ ) and Scn5a-heterozygousknockout (Scn5a +/− ) mice. The efficacy of Ex-527 in inhibiting Sirt1 was verified by documenting increased acetylation of Na v 1.5 on K1479 (Supplementary Fig. 6c ) and activation of the unfolded protein response (Supplementary Fig. 6d ) in the hearts of treated Scn5a +/+ mice. Scn5a +/+ mice treated with Ex-527 showed prolongation of the QTc and a strong trend toward QRS prolongation as compared to control mice (Supplementary Table 5 ). QRS prolongation reached significance in Scn5a +/− mice treated with Ex-527 (P = 0.05; Supplementary Table 5) . Thus, pharmacologic inhibition of Sirt1 recapitulates the same conduction abnormalities observed in aged cSirt1 −/− mice, and lack of one allele of Scn5a mice amplifies this phenotype. Also similarly to cSirt1 −/− mice, mice treated with Ex-527 did not show a decrease in cardiac connexin 43 ( Supplementary  Fig. 6b ), which indicates that Sirt1 likely does not regulate gapjunction conduction.
The increase in QRS and QTc interval duration in cSirt1 −/− mice prompted us to compare action-potential upstroke and duration in cSirt1 fl/fl and cSirt1 −/− cardiomyocytes. As compared to cSirt1 fl/fl cardiomyocytes, cSirt1 −/− cardiomyocytes showed decreased velocity of phase 0 of the action potential (Supplementary Fig. 3c )-consistent with a decrease in I Na -prolonged action-potential duration (Supplementary Fig. 3d )-no change in resting membrane potential (Supplementary Fig. 3e ) and no change in the amplitude of late I Na (Supplementary Fig. 3b ). These changes in action-potential duration and kinetics in cSirt1 −/− cardiomyocytes are consistent with the observed EKG abnormalities. (24 h), atrial fibrillation with a slow ventricular rate of ~120 beats/min at 5 h before death (5 h); sinus bradycardia at 160 beats/min at 1 h before death (1 h) and junctional escape rhythm at 120 beats/min at 30 min before death (30 min). In e, traces show normal sinus rhythm at 24 h before death (24 h), sinus bradycardia at 240 beats/min at 30 min before death (30 min) and complete heart block with a slow ventricular escape at 10 min before death (10 min). (f) Left, western blot showing expression of Na v 1.5, Sirt1 and acetylated-K1479-Na v 1.5 in ventricular tissue of hearts explanted from patients with dilated cardiomyopathy (CMP) as compared to hearts with normal function. GAPDH was used as loading control. Right, quantitation of Ace-K1479-Nav1.5 normalized to total Nav1.5 n = 4 normal and n = 7 CMP hearts, *P < 0.05 versus normal. (g) Photomicrographs showing acetyl-K1479-Na v 1.5 immunostaining in the heart of a patient with CMP and conduction abnormalities (CA; QRS 176 ms, QTc 511 ms) as compared to that of a normal heart. Representative images from CMP heart (n = 4) and normal heart (n = 3). Arrows, Ace-K1479-Na v 1.5. Scale bar, 50 µm. Independent sample t test was used for f and log-rank test was used for c. Uncropped blots are shown in Supplementary Figure 7 . Dot plots show mean (line), and error bars represent s.e.m.
To examine whether cardiac arrhythmias occur in cSirt1 −/− mice, we performed continuous ambulatory telemetry of 6-9-month-old mice. Telemetry monitoring showed nonsustained ventricular tachycardia (VT) in 4 of 12 cSirt1 −/− mice but in 0 of 10 Sirt1 fl/fl mice (P < 0.05; Fig. 4a and Supplementary Table 6 ). In addition, although there were no differences in heart rate (maximum, minimum or mean), frequent sinus pauses were present in 6 of 12 cSirt1 −/− mice, as compared to only 1 of 10 Sirt1 fl/fl mice (P < 0.05), and there was a trend toward more episodes of two-degree atrioventricular (AV) block in the cSirt1 −/− mice (Fig. 4b and Supplementary Table 6) . Moreover, cSirt1 −/− mice were at a markedly increased risk for premature death between the ages of 6 and 10 months (Fig. 4c) , the period during which they manifested abnormalities in cardiac electrical conduction and arrhythmias. Although the left ventricular-ejection fraction was mildly decreased in cSirt1 −/− as compared to cSirt1 fl/fl mice, cardiac output was not depressed in 5-6-month-old cSirt1 −/− mice, LV mass was not increased and no signs of clinical heart failure or pulmonary congestion were evident at this age (Supplementary Table 7) . We followed four cSirt1 −/− mice with long-term implanted telemetry monitors to identify the cause of death. Each of the mice developed marked bradyarrhythmias (sinus bradycardia with junctional-escape rhythms and/or AV block) within 12 h of death (Fig. 4d,e) , which suggests that cSirt1 −/− mice die of bradyarrhythmias.
Finally, we explored the potential significance of K1479 acetylation in human cardiac conduction disease by determining whether lysine acetylation of Na v 1.5 is associated with clinical conduction abnormalities. We obtained ventricular tissue from hearts explanted at the time of transplantation from patients with idiopathic dilated cardiomyopathy. Mean QRS and QTc were prolonged in these patients, as assessed by surface EKGs (Supplementary Table 8) . We compared Na v 1.5 expression and K1479 acetylation in these hearts to those of subjects who had no known heart disease, had normal left-ventricular function and had died of noncardiac-related causes. When compared to these normal human hearts, dysfunctional hearts with conduction abnormalities showed increased levels of Ace-K1479 Na v 1.5, with no decrease in Sirt1 expression (Fig. 4f,g ).
Several post-translational modifications govern trafficking of Na v 1.5 (ref. 2) . PKC-mediated phosphorylation of serine 1503 in the III-IV interdomain linker of the channel decreases its expression on the cell membrane 7, 11 . Moreover, the energetic state of the cell also regulates Na v 1.5 trafficking; NAD + and NADH have opposing effects on the membrane expression of the channel 6 . Notably, NADH acts via PKC to decrease membrane expression of Na v 1.5 (ref. 6). Our findings that Sirt1 plays an important part in regulating the trafficking of Na v 1.5 to the cell membrane dovetails with these prior reports, and suggests that NAD + -dependent, Sirt1-mediated deacetylation of K1479 in the III-IV interdomain linker counteracts PKC-mediated phosphorylation of S1503 in the same region of the channel. Given that Na v 1.5 trafficking is regulated by lysine ubiquitination 13 , as well as the role of Sirt1 in governing ubiquitination 14 , it is tempting to hypothesize a functional interaction between lysine acetylation and the ubiquitination of Na v 1.5.
Inherited human SCN5A channelopathies are associated with a wide range of cardiac conduction abnormalities and arrhythmia phenotypes. SCN5A mutations that decrease I Na can result in progressive cardiac conduction defects with widening of the QRS interval [15] [16] [17] , bundlebranch block 16 and dysfunction of the sinoatrial pacemaker, resulting in sinus block and bradycardia 15, 17, 18 . In addition, reduced expression of Na v 1.5 in Scn5a +/− mice leads to widespread conduction delay, as well as atrial and ventricular arrhythmias that worsen with age 12, 19 .
The heterogeneity of the conduction abnormalities and arrhythmias in cSirt1 −/− mice, as well as their association with aging, are reminiscent of the phenotype of Scn5a +/− mice and suggest a global slowing of conduction, probably most prominently in the specialized conduction system and periatrioventricular nodal tissue. Age-related worsening of conduction disease is also present in patients with loss-of-function SCN5A mutations (as seen in inherited conduction disease 20 and Brugada syndrome 21 ), and suggests that the loss of Sirt1-dependent I Na might add to the insults perpetrated by aging on the cardiac conduction system. Such insults include age-associated fibrosis 22 that could compound the decrease in I Na owing to lack of Sirt1. It is also possible that the decrease in I Na caused by deficiency in Sirt1 contributes to cardiac fibrosis, as has been reported in Scn5a +/− mice 12 .
The III-IV interdomain linker of Na v 1.5 is lysine-rich and is one of the most conserved regions of the protein. Several mutations or deletions involving lysines in this linker lead to abnormal Na v 1.5 function and are associated with human arrhythmias. The ∆KPQ deletion, encompassing residues 1505-1507, disrupts fast inactivation and results in an autosomal-dominant form of long-QT syndrome 23 . It also leads to higher peak current and changes in current gating 24 . A loss of function ∆K1500 mutation results in reduced peak sodium current, but a larger sustained (late) sodium current, and leads to an overlapping phenotype of a prolonged QT interval, QRS widening (right bundle-branch block) and sinus pauses 8 . Most germane to our findings, in a large family with a malignant phenotype, a deletion mutation affecting K1479 (∆K1479) was reported to cause Brugada syndrome, severe cardiac conduction disease, including prolonged sinus pauses, sudden cardiac death despite pacemaker placement, and sudden infant death syndrome 25 . When expressed in HEK293 cells, the Na v 1.5 channel bearing the ∆K1479 deletion resulted in both a decrease in the peak current density and marked changes in channel kinetics 9 . By contrast, we found that replacement of K1479-the primary site for Na v 1.5 acetylation-with a nonacetylatable residue alters membrane localization without inducing major changes in channel kinetics. The differences in the electrophysiological characteristics of Na v 1.5 ∆K1479 and Na v 1.5 with a nonacetylatable residue could be due to changes in protein folding caused by the deletion of K1479, but not by its replacement with a nonacetylatable residue, in this region of the protein, in which mutations of other amino acids are known to cause profound kinetic changes in the channel. Overall, these inherited human arrhythmia phenotypes, coupled with changes in Na v 1.5 function and/or trafficking, underscore the important role of K1479 in regulating the cardiac sodium current.
Our findings on Sirt1-dependent regulation of Na v 1.5 shed light on the role of K1479 not only in inherited forms of arrhythmia, but also in conditions that lead to acquired arrhythmias. Reduction of I Na is typical in both experimental and human heart failure [26] [27] [28] . The finding that Na v 1.5 is hyperacetylated at K1479 in patients with dilated cardiomyopathy and conduction disease suggests that the K1479-acetylation-mediated decline of I Na might play a part in brady-and tachyarrhythmias associated with advanced human heart failure. It is important to note, however, that Sirt1 expression did not differ substantially between cardiomyopathic and normal hearts. Although this finding does not argue against the potential role of K1479 acetylation in human cardiac conduction disease, it does indicate that K1479 acetylation of Na v 1.5 in this particular cohort of patients is due to mechanisms other than Sirt1 deficiency. Changes in the expression or activity of nonsirtuin HDACs or acetyltransferases could provide for such alternative mechanisms. It is also important to recognize that decreased expression or activity of cardiac Sirt1 could, via its effect on Na v 1.5, lead indirectly to structural changes in the heart. Ion channel dysfunction can result in mechanical instability, ultimately leading to cardiac remodeling, as is evident in humans who harbor arrhythmogenic mutations in SCN5A and develop dilated cardiomyopathy 29 , and in Scn5a +/− mice, which develop cardiac hypertrophy and fibrosis as they age 12 .
Our findings do not exclude a role for other sirtuins or nonsirtuin HDACs in the modulation of cardiac electrophysiology. The finding that TSA alters K1479 acetylation suggests that K1479 acetylation is regulated by more than one HDAC, which is concordant with previous findings that many acetylated lysines targeted by Sirt1 are also deacetylated by nonsirtuin HDACs 30 . Deacetylation-mediated regulation of I Na by HDACs other than Sirt1 might provide a redundant mechanism for K1479 deacetylation and explain why cSirt1 −/− mice had only a modest reduction in I Na and survived into adulthood; a compensatory increase in Na v 1.5 protein expression is another explanation for the modest reduction of I Na in cSirt1 −/− mice. We also cannot rule out the possibility that Sirt1 might affect the trafficking and/or function of other ion channels. The QTc prolongation seen in cSirt1 −/− mice could be the result of changes in the expression or function of K + channels, Ca 2+ channels or Ca 2+ -handling proteins.
In summary, these findings show that dynamic lysine acetylation, modulated by the Sirt1 deacetylase, is a functional post-translational modification of the cardiac sodium channel. By deacetylating Na v 1.5 at K1479, Sirt1 stimulates its trafficking to the cell membrane and thus has an important role in the regulation of cardiac electrical activity. Consistent with its effect on I Na , lack of cardiomyocyte Sirt1 in mice leads to cardiac conduction abnormalities and fatal arrhythmias. These findings suggest that pharmacological or genetic interventions that activate Sirt1 might be of benefit in treating cardiac arrhythmias that result from familial or acquired loss-of-function sodium channelopathies.
MeTHodS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
oNLINe MeTHodS
Animals. Sirt1 floxed mice (Sirt1 fl/fl ; Jackson Laboratories 008041, backcrossed into C57BL/6) were mated with mice overexpressing Cre-recombinase driven by the α-myosin heavy chain promoter (αMHC-Cre; Jackson Laboratories 011038, C57BL/6 background) to generate cSirt1 −/− mice and littermate Sirt1 fl/fl controls. 4-9-month-old male and female mice were used. All studies were approved by the Institutional Animal Care and Use Committees (IACUC) at the University of Iowa.
Reagents. Na v 1.5 (abcam-ab63288, Almone labs-ASC-005, Millipore-AB5493), Sirt1 (Thermo Scientific-PA5-23-063, Santa Cruz Biotechnologysc-15404), GAPDH (Trevigen-2275-PC), custom designed anti-acetyl-K1479 Na v 1.5 (YenZym Antibodies) and acetyl-lysine (Cell signaling technology-9681) antibodies were used. A custom designed anti-acetyl-K1479 Na v 1.5 antibody was purified from sera from rabbits immunized with the peptide FNQQKK1479KAcLGGQDIC. The specificity of this antibody was determined by examining its ability to detect p300/CBP acetyltransferase-induced acetylation of III-IV interdomain linker of Na v 1.5 and not the nonacetylated linker (Supplementary Fig. 6c ). All other reagents were procured from Sigma-Aldrich, St. Louis, MO, unless specified. The SCN5A mutant constructs were generated by site-directed mutagenesis. Ex-243 and Ex-527 are specific inhibitors of Sirt1, whereas Ex-242 is an optical isomer of Ex-243 with no activity toward Sirt1.
Cell culture. HEK293 cells were obtained from the American Type Culture Collection (ATCC) and were cultured in 10% FBS-supplemented DMEM media. Rat neonatal cardiomyocytes were freshly isolated and cultured in an equivolume mixture of DMEM and F-12 media containing 5% FBS.
Rat neonatal cardiomyocyte isolation. Cardiomyocytes were isolated from newly delivered neonatal Sprague-Dawley rat pups using the neonatal cardiomyocyte isolation system (Worthington Biochemical Co, Lakewood, NJ).
Isolation of mouse ventricular myocytes.
Mouse ventricular myocytes were isolated from 6-7-month-old cSirt1 −/− and Sirt1 fl/fl control hearts by perfusing a Ca 2+ -free normal Tyrode solution containing collagenase (1 mg/ml, Type II, Worthington Biochemical, USA) and protease (0.1 mg/ml, Sigma-Aldrich, USA) on a Langendorff apparatus at 37 °C, as described 31 Immunoprecipitation and immunoblotting. Immunoprecipitation of Sirt1, Na v 1.5 and GST-Na v 1.5 (III-IV) was carried out by incubating 2 µg of the respective antibodies (Santa Cruz Biotechnology and Millipore) with 1 mg of cell lysate or tissue homogenate overnight, followed by 40 µl of protein A-Sepharose slurry (Amersham, Piscataway, NJ) for 4 h. After washing, immunoprecipitates were boiled in SDS-PAGE gel loading buffer, subjected to SDS-PAGE, transferred to nitrocellulose membrane and probed with 1:1,000 dilution of specified primary antibody and the appropriate peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology). Western blotting of 50 µg of whole-cell lysates (WCL) was similarly performed by using appropriate primary and secondary antibodies. Chemiluminescent signal was developed by using SuperSignal West Pico/Femto substrate (Pierce, Rockford, IL), and blots were imaged with a GelDoc 2000 Chemi Doc system (Bio-Rad, Hercules, CA). Supplementary Figure 8 shows uncropped blots for Supplementary Figures.
Acetylation and deacetylation of Na v 1.5. For analysis of in vitro acetylation and deacetylation of Na v 1.5 constructs, we followed established protocols 32 . Purified recombinant GST-Na v 1.5 (III-IV) or GST-K1479A-Na V 1.5 (III-IV) was desalted, and the buffer was exchanged with acetylation buffer (50 mM Tris·HCl, pH 8.0/137 mM NaCl/0.1 mM EDTA, pH 8.0/10% glycerol/1 mM DTT/0.1 mM PMSF/2 µM trichostatin A) using Zeba spin columns (Pierce).
Five micrograms of Na v 1.5 construct per acetylation reaction were incubated with acetyl-CoA (20 µM) and p300/CBP acetyltransferase (60 units, Active Motif) at 30 °C for 40 min with shaking. The acetylation reaction was followed immediately by the deacetylation reaction by adding deacetylation buffer (25 mM Tris·HCl, pH 8.0/137 mM NaCl/2.7 mM KCl/1 mM MgCl 2 / 1 mg/ml BSA), 1 mM NAD + and active recombinant Sirt1 (10 units; Biomol, Plymouth Meeting, PA), and incubated at 37 °C for 1 h with shaking. The reaction mixture was subjected to SDS-PAGE and immunoblotting. Acetylation of Na v 1.5 and GST-Na v 1.5 (III-IV) in cells was assessed by immunoprecipitation followed by immunoblotting with an acetyl-lysine-specific antibody (Cell Signaling). Acetylation of K1479 in mouse and human tissues was assessed using the custom acetyl-K1479 antibody.
Determination of cell surface expression of Na v 1.5 in HEK293 cells. A stable HEK293 cell line expressing full-length Na v 1.5 tagged with an extracellular FLAG-myc epitope was created. Cells were plated in a 12-well dish at a density of 1.0 × 10 5 cells/well and placed on ice to stop cellular trafficking throughout experiment. Nonpermeabilized cells were then treated with primary α-FLAG-M2 antibody (1:50 in PBS/0.5% BSA) (Covance, New York, NY) for 90 min followed by washing with 1×-PBS/0.5% BSA (3×). Cells were then treated with a FITC conjugated-goat anti-mouse secondary antibody (1:1,000) (Sigma-Aldrich, St. Louis, MO) for 30 min in the dark. Cells were washed again with only 1×-PBS and treated with DAPI (0.5 µg/ml) for 1 min followed by a 5-min rinse in 1× PBS. Cells were imaged with a Leica TCS-SL confocal microscope and captured with Leica confocal software (Leica Microsystems, Mannheim, Germany).
Cell surface expression of wild-type Na v 1.5 and K1479A-Na v 1.5 was quantified by chemiluminescence. The wild-type and mutant constructs were expressed in HEK293 cells. Nonpermeabilized cells were labeled sequentially with an antibody that detects an extracellular domain of Na V 1.5 (Abcam) followed by secondary secondary horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG. All steps were performed at 4 °C to block Na v 1.5 trafficking. The cells were then washed extensively, and HRP-labeled proteins were detected using SuperSignal West Femto chemiluminescent substrate (Pierce) and read in a TD20/20 luminometer (Turner, Sunnyvale, CA). Background chemiluminescence was established with HEK293 cells not expressing Na v 1.5.
Adult mouse cardiomyocytes on laminin-coated coverslips were fixed, blocked and incubated with 1:100 anti-Na v 1.5 antibody (Abcam, ab62388), which detects the extracellular domain of Na v 1.5, overnight. The antigen-antibody complexes were probed with 1:1,000 AlexaFluor568 tagged anti-mouse secondary antibody and counterstained with DAPI. Images were acquired to detect fluorescence of AlexaFluor568, DAPI along with transmitted light imaging using a Zeiss confocal microscope (Model 710). The surface expression of Na v 1.5 was determined by quantifying the fluorescence intensity of immunostaining for Na v 1.5 on the cell boundary using ImageJ (1.49e) software. The cell boundary was determined by simultaneous transmitted light microscopy.
Immunohistochemistry. Sections (5 µm) of formalin-fixed paraffin-embedded tissues were heated (95 °C, 20 min) in citrate buffer (10 mM) for antigen retrieval followed by incubation with primary antibody. Antigen-primary antibody complexes were incubated with a polyvalent biotinylated goat anti-rabbit secondary antibody and streptavidin peroxidase (STV-HRP) system to amplify the signals, followed by detection with diaminobenzidine (DAB) as a chromogen. Slides were counterstained with hematoxylin, dehydrated with alcohols and xylene and mounted in DPX. Images were captured by a charged coupled device (CCD) camera attached with the Olympus microscope (Model BX61).
Whole-cell patch clamping. Conventional whole-cell patch clamp techniques were used to record Na + currents from HEK293 cells constitutively expressing Na v 1.5 and GFP, from rat neonatal cardiomyocytes, or from rodshaped, quiescent single isolated mouse ventricular myocytes. For HEK293 cells, the electrodes of 1-2 MΩ were filled with a pipette solution containing (in mmol/liter) NaF 10, CsF 110, CsCl 20, EGTA 10 and HEPES 10 (pH 7.35 with CsOH), and the bath solution contained (in mmol/liter) NaCl 40, 103 NMDG, KCl 4.5, CaCl 2 1.5, MgCl 2 1, and HEPES 10 (titrated to pH 7.35 with
